Asundexian Approval Nears: Who Should Wait and Who Needs DAPT Now
An asundexian approval decision now sits with the FDA under priority review. Here is how to weigh the evidence against the antiplatelet choice you make today.
The short version
- An asundexian approval would deliver the first factor XIa inhibitor for secondary stroke prevention — added to antiplatelet therapy, not replacing it.
- In the 12,327-patient OCEANIC-STROKE trial, ischemic stroke fell from 8.4% to 6.2%, with no significant excess bleeding.
- Nothing supports deferring guideline antiplatelet therapy while the agency deliberates.
Why Asundexian Approval Is in the News Right Now
The asundexian approval clock started on May 19, 2026, when the FDA accepted Bayer’s new drug application and granted priority review for recurrent stroke prevention after non-cardioembolic ischemic stroke or transient ischemic attack (TIA). Priority review shortens the timeline but says nothing about the outcome; no action date is public.
Investigators presented full OCEANIC-STROKE results at the International Stroke Conference on February 5, 2026, and the New England Journal of Medicine published them on April 16. The drug is still investigational everywhere.
That leaves a live gap: stroke services are choosing antiplatelet regimens today for exactly the patients this trial enrolled, long before any decision lands.
The Background: Why Factor XIa Became the Target
Antiplatelet therapy remains the backbone here, and short-course dual antiplatelet therapy (DAPT) is the main way to intensify it early. The 2026 American Heart Association/American Stroke Association acute stroke guideline recommends aspirin plus clopidogrel within 24 hours for minor stroke or high-risk TIA, continued 21 days, then a single agent.
That ceiling is deliberate. Pooled CHANCE and POINT data place the benefit of dual therapy in roughly the first three weeks, while long-term trials such as MATCH and CHARISMA saw ischemic gains cancelled by cumulative bleeding.
Factor XIa (FXIa) amplifies thrombus growth but contributes little to the initial hemostatic plug. People born with low factor XI have less ischemic stroke without excess intracranial bleeding, the argument for uncoupling thrombosis from hemostasis. The class has stumbled: Bayer halted OCEANIC-AF in 2023 when asundexian proved inferior to apixaban in atrial fibrillation.
The Evidence So Far
OCEANIC-STROKE randomized 12,327 patients within 72 hours of a non-cardioembolic ischemic stroke or high-risk TIA. All received planned antiplatelet therapy — single agent in 37%, dual in 63% — plus asundexian 50 mg daily or placebo. Mean age was 68, median National Institutes of Health Stroke Scale (NIHSS) score 2, median follow-up 567 days.
Ischemic stroke, the primary endpoint, occurred in 6.2% versus 8.4%, a 26% relative reduction (cause-specific hazard ratio [csHR] 0.74; 95% confidence interval [CI] 0.65–0.84; P<0.001). That is an absolute reduction of 1.9 percentage points at one year, a number needed to treat (NNT) near 53. Stroke of any type fell from 8.8% to 6.6%, disabling or fatal stroke from 3.0% to 2.1%, and the composite of cardiovascular death, myocardial infarction or stroke from 11.1% to 9.2% (csHR 0.83; 95% CI 0.74–0.92).
Major bleeding by International Society on Thrombosis and Haemostasis (ISTH) criteria occurred in 1.9% versus 1.7% (csHR 1.10; 95% CI 0.85–1.44; P=0.46), and major or clinically relevant non-major bleeding in 5.5% versus 5.0%. Neither difference was significant; the point estimates imply a number needed to harm (NNH) near 500.
The Practical Question: Asundexian Approval Versus DAPT Today
Holding a patient for asundexian does not survive the trial design. OCEANIC-STROKE never withheld antiplatelet therapy; the drug was layered on top of the planned regimen. An asundexian approval would add an agent, not displace DAPT.
The bedside decision is therefore unchanged. Start guideline antiplatelet therapy on schedule, hold the 21-day dual window, and step down to monotherapy rather than stretching DAPT for a drug with no label.
Who looked like a candidate in the trial
- Non-cardioembolic ischemic stroke with NIHSS 15 or below, or high-risk TIA with an ABCD2 risk score of 6 or 7
- At least one atherosclerotic feature: non-lacunar infarct, known atherosclerosis, or plaque on cerebrovascular imaging
- Randomized within 72 hours of onset; 27.4% had thrombolysis, thrombectomy or both
- Excluded: atrial fibrillation or another cardioembolic source needing anticoagulation, and dialysis-dependent renal failure
The preparatory work worth doing is diagnostic. Completing the atherosclerotic and rhythm work-up identifies future candidates and rules others out: a patient whose monitoring reveals atrial fibrillation moves to anticoagulation and leaves this population. Purely lacunar syndromes without plaque or atherosclerosis were never enrolled.
Where Experts Disagree
Enthusiasm centers on a long-felt gap. Richa Sharma, MD, a Yale School of Medicine stroke neurologist not involved in the trial, told TCTMD the result “expands our armamentarium of secondary stroke prevention tools.”
Asundexian appears to be a very promising option for secondary prevention. Marion Boulanger, MD, PhD, in an accompanying New England Journal of Medicine editorial
Her caution follows immediately: five- to ten-year follow-up is needed before anyone can conclude net clinical benefit holds. Richa Sharma flagged the same unknowns: treatment duration, whether use becomes lifelong, and cost.
The dispute is about durability and selection, not the result. The upper bound of the bleeding confidence interval, 1.44, does not exclude a modest excess, and both bleeding endpoints drifted upward. Conflicts of interest (COI) matter: Bayer sponsored the trial, and principal investigator Mike Sharma, MD, reports consulting fees and institutional research funding from the company.
What to Watch For
- An asundexian approval decision is pending under FDA priority review, with no disclosed action date.
- Whether a label mirrors trial eligibility or reads more broadly.
- Phase 3 milvexian results in secondary stroke prevention, due in the fourth quarter of 2026, testing for a class effect.
- Durability data, and where a future guideline places the drug against the 21-day DAPT window.
- Price and coverage, which decide how much of the eligible population is treated.
Until a label exists, the useful action is administrative: complete the mechanism work-up, document the atherosclerotic findings, and keep a list of patients worth revisiting.
Sources
- Sharma M, Dong Q, Hirano T, et al. Asundexian for Secondary Stroke Prevention. N Engl J Med. 2026;394(15):1467-1479. OCEANIC-STROKE primary results in the New England Journal of Medicine
- Bayer. Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack. Bayer United States, May 19, 2026. Bayer announcement of FDA priority review for asundexian
- American Heart Association/American Stroke Association. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2026. 2026 AHA/ASA acute ischemic stroke guideline
- European Stroke Organisation. European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA. European Stroke Journal. ESO recommendation on short-term dual antiplatelet therapy and its duration evidence
- Neale T. OCEANIC-STROKE: Asundexian Prevents Recurrent Strokes, With No Added Bleeding. TCTMD, February 9, 2026. TCTMD report on the OCEANIC-STROKE presentation at ISC 2026
- American College of Cardiology. OCEANIC-STROKE: Asundexian Lowers Recurrent Stroke Risk in Patients With Noncardioembolic Stroke or TIA. ACC Journal Scan, April 22, 2026. ACC journal scan covering the trial and its accompanying editorial
- Ciccone I. Newly Published Phase 3 OCEANIC-STROKE Trial Data Show Asundexian Reduces Recurrent Ischemic Stroke Risk. NeurologyLive, April 16, 2026. NeurologyLive summary of the published OCEANIC-STROKE outcomes
- Bayer’s experimental blood-thinner notches trial win in stroke prevention. BioPharma Dive, November 24, 2025. BioPharma Dive analysis of the factor XIa class and milvexian timelines